Objective The optimal potential of chemotherapy, despite being the standard treatment, has not yet been achieved and instead it can lead to adverse toxicological effects as a result of off-target toxicity, as the drug cannot discriminate between healthy and cancerous cells. Small molecule prodrugs help solve this issue thanks to their high efficiency in targeting tumour cells. Syndivia have developed the next-generation Antibody Drug Conjugation platform for development of highly effective small molecule prodrugs for targeted cancer therapies. Two patented technologies are applied in the formulation of the prodrugs delivering higher plasma stability and controlled release at the tumour site resulting in a higher therapeutic efficiency and reduction of off-target toxicity of the chemotherapeutic. The pioneer product SDV1001 is specifically focused on treatment of pancreatic cancer, that accounts for the highest mortality rate among all cancers, over 74% of patients will not survive 1 year from time of diagnosis and 95% will die within 5 years. Preclinical trials have proven the efficacy of the product in which animals treated by SDV1001 displayed 92-100% tumour regression and no noticeable side effects. The Phase 1 project will be focused on establishing a complete and scalable supply chain, verifying the business model and commercialization strategy, planning new collaborations and partnerships, including the ones to implement the next clinical trials stage. Fields of science social sciencessociologydemographymortalitysocial scienceseconomics and businessbusiness and managementbusiness modelsmedical and health sciencesclinical medicineoncologypancreatic cancermedical and health sciencesbasic medicinetoxicology Programme(s) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.3. - Treating and managing disease Topic(s) SMEInst-05-2016-2017 - Supporting innovative SMEs in the healthcare biotechnology sector Call for proposal H2020-SMEInst-2016-2017 See other projects for this call Sub call H2020-SMEINST-1-2016-2017 Funding Scheme SME-1 - SME instrument phase 1 Coordinator SYNDIVIA Net EU contribution € 50 000,00 Address 650 BOULEVARD GONTHIER D'ANDERNACH 67400 ILLKIRCH GRAFFENSTADEN France See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Grand Est Alsace Bas-Rhin Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 71 429,00
